The optimal treatment regimens for NSCLC according to PD-L1 expression level and different pathological types.

Figshare2023-04-18 更新2026-04-28 收录

数据链接：

https://figshare.com/articles/dataset/The_optimal_treatment_regimens_for_NSCLC_according_to_PD-L1_expression_level_and_different_pathological_types_/22653446 数据链接链接失效反馈

官方服务：

资源简介：

The optimal treatment regimens for NSCLC according to PD-L1 expression level and different pathological types.

创建时间：

2023-04-18

Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer Table 1

非小细胞肺癌治疗

免疫联合疗法

Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer Table 1

DataCite Commons2024-05-15 更新40

4-1BB Co-stimulation Further Enhances Anti-PD-1-Mediated Reinvigoration of Exhausted CD39+ CD8 T Cells from Primary and Metastatic sites of Epithelial Ovarian Cancers. 4-1BB Co-stimulation Further Enhances Anti-PD-1-Mediated Reinvigoration of Exhausted CD39+ CD8 T Cells from Primary and Metastatic sites of Epithelial Ovarian Cancers

肿瘤免疫治疗

T细胞功能分析

4-1BB Co-stimulation Further Enhances Anti-PD-1-Mediated Reinvigoration of Exhausted CD39+ CD8 T Cells from Primary and Metastatic sites of Epithelial Ovarian Cancers Overall design: Compare gene expr

NIAID Data Ecosystem20

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors [cell lines]

肿瘤免疫治疗

KRAS突变肺癌

Lung cancer is the leading cause of cancer mortality worldwide. KRAS oncogenes are responsible for at least a quarter of lung adenocarcinomas, the main subtype of lung cancer. After four decades of in

NIAID Data Ecosystem10

Exon array analysis of the response to bevacizumab/erlotinib in advanced non-small cell lung cancer. Homo sapiens

非小细胞肺癌治疗

外显子生物标志物发现

In the current study, we used exon arrays and clinical samples from a previous trial (SAKK 19/05) to investigate the expression variations at the exon-level of 3 genes potentially playing a key role i

NIAID Data Ecosystem20

Characterization of Natural Killer Cell Sensitivity of Circulating Tumor Cells in Non-small Cell Lung Cancer using Bulk RNA-sequencing. Characterization of Natural Killer Cell Sensitivity of Circulating Tumor Cells in Non-small Cell Lung Cancer using Bulk RNA-sequencing

肿瘤免疫治疗

NK细胞毒性

To investigate whether circulating tumor cells exhibit NK sensitive gene expression profiles, we performed bulk RNA-sequencing on NK sensitive and NK resisitant cell lines, including two in-house deri

NIAID Data Ecosystem10

The optimal treatment regimens for NSCLC according to PD-L1 expression level and different pathological types.

资源简介：

相关数据集